Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants

Authors
Shin, J.Lee, E.H.Lee, J.H.Choi, B.M.Hong, Y.S.
Issue Date
2017
Publisher
Korean Pediatric Society
Keywords
B-type natriuretic peptide; Ibuprofen; Patent ductus arteriosus; Preterm infant
Citation
Korean Journal of Pediatrics, v.60, no.6, pp.175 - 180
Indexed
SCOPUS
KCI
Journal Title
Korean Journal of Pediatrics
Volume
60
Number
6
Start Page
175
End Page
180
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/86129
DOI
10.3345/kjp.2017.60.6.175
ISSN
1738-1061
Abstract
Purpose: Plasma level of B-type natriuretic peptide (BNP), an emerging, sensitive, and specific biomarker of hemodynamically significant patent ductus arteriosus (PDA), rapidly decreases in infants receiving cyclooxygenase inhibitors for ductal closure. We investigated the usefulness of serial BNP measurement as a guide for individual identification of early constrictive responses to ibuprofen in preterm infants with symptomatic PDA (sPDA). Methods: Before March 2010, the standard course of pharmacological treatment was initiated with indomethacin (or ibuprofen) and routinely followed by 2 additional doses at intervals of 24 hours. After April 2010, individualized pharmacological treatment was used, starting with the first dose of ibuprofen and withholding additional ibuprofen doses if the BNP concentration was <600 pg/mL and clinical symptoms of PDA improved. Results: The BNP-guided group received significantly fewer doses of ibuprofen than the standard group did during the first course of treatment and the entire study period. The need for further doses of cyclooxygenase inhibitors and for surgical ligation was not significantly different between the 2 groups. No significant differences were seen in clinical outcomes and/or complications related to sPDA and/or pharmacological treatment. Conclusion: Individualized BNP-guided pharmacological treatment may be used clinically to avoid unnecessary doses of cyclooxygenase inhibitors without increasing the ductal closure failure and the short-term morbidity related to sPDA. © 2017 by The Korean Pediatric Society.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choi, Byung Min photo

Choi, Byung Min
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE